+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ophthalmic AAV Gene Therapy Market - Global Forecast 2026-2032- Product Image
Ophthalmic AAV Gene Therapy Market - Global Forecast 2026-2032- Product Image
Sale

Ophthalmic AAV Gene Therapy Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6140466
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ophthalmic AAV Gene Therapy Market is projected to reach USD 1.66 Billion in 2026. It is expected to continue growing at a CAGR of 21.52%, reaching USD 5.42 Billion by 2032.

Ophthalmic AAV Gene Therapy: Executive Overview

Ophthalmic adeno-associated virus (AAV) gene therapy is advancing through a combination of clinical innovation, regulatory learning, and evolving delivery science. The field targets inherited retinal diseases and other disorders in which localized genetic treatment may address underlying biology rather than only symptoms. Progress remains dependent on durable expression, retinal access, patient selection, manufacturing consistency, and long-term safety monitoring.

Delivery, Durability, and Regulation Are Reshaping Development

The landscape is shifting from proof-of-concept studies toward more demanding evidence on durability, functional benefit, and clinically meaningful endpoints. Subretinal delivery remains important, while intravitreal and other approaches seek to reduce surgical burden and broaden retinal access. Developers must also manage immune responses, neutralizing antibodies, vector dose, repeat-administration limitations, manufacturing comparability, and post-treatment surveillance. These factors increasingly influence trial design, treatment-center requirements, and adoption readiness.

Artificial Intelligence Strengthens the Evidence and Delivery Pipeline

Artificial intelligence is contributing to ophthalmic AAV development through image analysis, retinal phenotyping, biomarker discovery, and trial-enrollment support. Machine-learning tools can help quantify changes in optical coherence tomography, fundus imaging, and visual-function measures, potentially improving endpoint sensitivity and reducing interpretation variability. AI may also support vector design, manufacturing process monitoring, and identification of patients most likely to benefit. Its value depends on representative datasets, clinical validation, transparent performance standards, and careful protection of patient data.

Regional Insights: Capabilities and Access Conditions Differ

North America combines advanced retinal research, specialized surgical capacity, and established regulatory experience, while Latin America is shaped by uneven access to genetic testing, referral networks, and advanced treatment centers. Europe benefits from strong academic collaboration and coordinated regulatory frameworks, although reimbursement and national health-technology assessment requirements vary. The Middle East is investing in specialized healthcare infrastructure but faces concentration of expertise in selected hubs. Africa has substantial unmet need and expanding research interest, alongside constraints in diagnostics, cold-chain logistics, and specialist availability. Asia-Pacific presents strong clinical and biotechnology capabilities in several markets, with access, regulatory pathways, and infrastructure differing widely across the region.

Group Insights: Policy Alignment and Research Networks Matter

ASEAN countries face varied diagnostic capacity, regulatory maturity, and specialist access, making regional collaboration important. BRICS economies combine significant research potential with different public-health priorities, manufacturing capabilities, and reimbursement environments. The European Union benefits from shared scientific and regulatory coordination, but implementation remains nationally differentiated. G7 members generally provide mature research ecosystems, advanced imaging, and specialized care pathways, while evidence and affordability requirements remain demanding. NATO countries may benefit from extensive biomedical networks and cross-border research links, although healthcare systems and treatment-access policies remain distinct. GCC states are developing high-end clinical infrastructure and can serve as regional referral hubs, provided workforce development and long-term follow-up systems keep pace.

Country Insights: Distinct Regulatory and Clinical Priorities

Australia supports specialist ophthalmic research and geographically dispersed care models. Brazil and Mexico must address diagnostic reach and regional treatment concentration. Canada combines strong research institutions with considerations related to provincial access and reimbursement. China, Japan, and South Korea have substantial biomedical capabilities, with regulatory and clinical pathways that require local evidence and operational expertise. India offers growing genetic-medicine capability alongside major affordability and access challenges. France, Germany, Italy, Spain, and the United Kingdom operate within sophisticated European research and healthcare systems, but assessment, funding, and implementation mechanisms differ. The United States remains a major center for translational research, clinical trials, specialized surgery, and regulatory precedent. Russia’s development environment is influenced by research capacity, healthcare-system conditions, and international collaboration constraints.

Leadership Priorities for Responsible Commercial and Clinical Progress

Industry leaders should prioritize durable clinical outcomes, standardized functional and imaging endpoints, and transparent long-term follow-up. Investment in genetic diagnosis and referral networks can improve identification of suitable patients before treatment. Manufacturing strategies should emphasize reproducibility, potency testing, supply resilience, and comparability across process changes. Organizations should build treatment-center readiness through surgeon training, multidisciplinary protocols, patient-selection criteria, and adverse-event management. Partnerships with regulators, payers, patient groups, and academic centers can clarify evidence expectations and support equitable access. AI initiatives should remain clinically validated, auditable, privacy-preserving, and integrated into-not substituted for-expert decision-making.

Research Methodology: Evidence-Led Assessment of Ophthalmic AAV Therapy

This executive summary applies a qualitative synthesis of the supplied market scope and established scientific, clinical, regulatory, and healthcare-delivery considerations relevant to ophthalmic AAV gene therapy. The assessment organizes findings across delivery technologies, therapeutic development, manufacturing, artificial intelligence, regional systems, country conditions, and stakeholder priorities. It deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Conclusions should be updated as peer-reviewed evidence, clinical-trial results, regulatory decisions, and real-world follow-up become available.

Conclusion: Durable Evidence and Delivery Readiness Will Define Progress

Ophthalmic AAV gene therapy is moving toward a more rigorous phase in which biological promise must be matched by durable benefit, safe administration, scalable manufacturing, and practical patient access. Regional and national differences will shape how quickly innovation reaches care. Leaders that combine robust evidence generation with treatment-center readiness, responsible AI use, genetic-diagnosis infrastructure, and long-term patient support will be best positioned to advance the field responsibly.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Ophthalmic AAV Gene Therapy Market, by Indication
7.1. Introduction
7.2. Choroideremia
7.3. Leber Congenital Amaurosis
7.4. Retinitis Pigmentosa
7.5. Stargardt Disease
8. Ophthalmic AAV Gene Therapy Market, by Vector Type
8.1. Introduction
8.2. AAV2
8.3. AAV8
8.4. AAV9
9. Ophthalmic AAV Gene Therapy Market, by Administration Route
9.1. Introduction
9.2. Intravitreal Injection
9.3. Subretinal Injection
9.4. Suprachoroidal Injection
10. Ophthalmic AAV Gene Therapy Market, by Clinical Phase
10.1. Introduction
10.2. Phase I
10.3. Phase II
10.4. Phase III
10.5. Preclinical
11. Ophthalmic AAV Gene Therapy Market, by Therapy Line
11.1. Introduction
11.2. First-Line
11.3. Second-Line
11.4. Third-Line
12. Ophthalmic AAV Gene Therapy Market, by End User
12.1. Introduction
12.2. Hospitals
12.2.1. Academic Hospitals
12.2.2. Community Hospitals
12.3. Research Institutes
12.3.1. Government Institutes
12.3.2. Private Research Institutes
12.4. Specialty Clinics
12.4.1. Ophthalmic Centers
12.4.2. Retina Clinics
13. Ophthalmic AAV Gene Therapy Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Ophthalmic AAV Gene Therapy Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Ophthalmic AAV Gene Therapy Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Ophthalmic AAV Gene Therapy Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Adverum Biotechnologies, Inc.
18.3. Applied Genetic Technologies Corporation
18.4. Avista Therapeutics
18.5. Biogen Inc.
18.6. Cyagen Biomodels LLC
18.7. Editas Medicine, Inc.
18.8. Homology Medicines, Inc.
18.9. MeiraGTx Holdings plc
18.10. Neurophth Therapeutics, Inc.
18.11. Ocugen, Inc.
18.12. Otsuka Pharmaceutical Co., Ltd.
18.13. Regenxbio, Inc.
18.14. Spark Therapeutics, Inc.
18.15. ViGeneron GmbH
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Ophthalmic AAV Gene Therapy Market, Years Considered for the Study
FIGURE 2. Global Ophthalmic AAV Gene Therapy Market, Research Design
FIGURE 3. Global Ophthalmic AAV Gene Therapy Market, Research Framework
FIGURE 4. Global Ophthalmic AAV Gene Therapy Market, Data Triangulation
FIGURE 5. Global Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Ophthalmic AAV Gene Therapy Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Ophthalmic AAV Gene Therapy Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2025 vs 2032 (%)
FIGURE 9. Global Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 11. Global Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2025 vs 2032 (%)
FIGURE 13. Global Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2025 vs 2032 (%)
FIGURE 15. Global Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Ophthalmic AAV Gene Therapy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Ophthalmic AAV Gene Therapy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 19. Global Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Ophthalmic AAV Gene Therapy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Ophthalmic AAV Gene Therapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Ophthalmic AAV Gene Therapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Ophthalmic AAV Gene Therapy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Ophthalmic AAV Gene Therapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Ophthalmic AAV Gene Therapy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Ophthalmic AAV Gene Therapy Market Segmentation & Coverage
TABLE 2. Global Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 3. Global Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Choroideremia Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Choroideremia Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Choroideremia Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Leber Congenital Amaurosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Leber Congenital Amaurosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Leber Congenital Amaurosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Retinitis Pigmentosa Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Retinitis Pigmentosa Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Retinitis Pigmentosa Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Stargardt Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Stargardt Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Stargardt Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 17. Global AAV2 Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global AAV2 Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global AAV2 Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global AAV8 Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global AAV8 Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global AAV8 Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global AAV9 Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global AAV9 Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global AAV9 Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 27. Global Intravitreal Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Intravitreal Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Intravitreal Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Subretinal Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Subretinal Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Subretinal Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Suprachoroidal Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Suprachoroidal Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Suprachoroidal Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 37. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 50. Global First-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global First-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global First-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Second-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Second-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Second-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Third-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Third-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Third-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 60. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Academic Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Academic Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Academic Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Community Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Community Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Community Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Government Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Government Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Government Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Private Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Private Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Private Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Ophthalmic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Ophthalmic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Ophthalmic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Retina Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Retina Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Retina Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 88. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Ophthalmic AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 109. North America Ophthalmic AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. North America Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 111. North America Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 112. North America Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 113. North America Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 114. North America Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 115. North America Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. North America Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 117. North America Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 118. North America Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 119. North America Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 120. Latin America Ophthalmic AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Latin America Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. Latin America Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 123. Latin America Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 124. Latin America Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 125. Latin America Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 126. Latin America Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. Latin America Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 128. Latin America Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 129. Latin America Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 130. Latin America Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 131. Europe Ophthalmic AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Europe Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 133. Europe Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 134. Europe Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 135. Europe Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 136. Europe Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 137. Europe Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Europe Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 139. Europe Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 140. Europe Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 141. Europe Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 142. Middle East Ophthalmic AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Middle East Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. Middle East Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 145. Middle East Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 146. Middle East Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 147. Middle East Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 148. Middle East Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. Middle East Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 150. Middle East Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 151. Middle East Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 152. Middle East Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 153. Africa Ophthalmic AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Africa Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 155. Africa Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 156. Africa Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 157. Africa Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 158. Africa Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 159. Africa Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Africa Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 161. Africa Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 162. Africa Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 163. Africa Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 164. Global Ophthalmic AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 168. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 169. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 170. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 171. ASEAN Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 173. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 174. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 175. ASEAN Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 176. GCC Ophthalmic AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 177. GCC Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. GCC Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 179. GCC Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 180. GCC Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 181. GCC Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 182. GCC Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. GCC Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 184. GCC Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 185. GCC Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 186. GCC Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 187. European Union Ophthalmic AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. European Union Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. European Union Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 190. European Union Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 191. European Union Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 192. European Union Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 193. European Union Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. European Union Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 195. European Union Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 196. European Union Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 197. European Union Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 198. BRICS Ophthalmic AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 199. BRICS Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 200. BRICS Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 201. BRICS Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 202. BRICS Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 203. BRICS Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 204. BRICS Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. BRICS Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 206. BRICS Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 207. BRICS Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 208. BRICS Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 209. G7 Ophthalmic AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 210. G7 Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 211. G7 Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 212. G7 Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 213. G7 Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 214. G7 Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 215. G7 Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. G7 Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 217. G7 Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 218. G7 Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 219. G7 Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 220. NATO Ophthalmic AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. NATO Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 222. NATO Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 223. NATO Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 224. NATO Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 225. NATO Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 226. NATO Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. NATO Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 228. NATO Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 229. NATO Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 230. NATO Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 231. Global Ophthalmic AAV Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 232. United States Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 233. United States Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. United States Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 235. United States Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 236. United States Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 237. United States Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 238. United States Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. United States Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 240. United States Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 241. United States Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 242. United States Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 243. Canada Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 244. Canada Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 245. Canada Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 246. Canada Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 247. Canada Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 248. Canada Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 249. Canada Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. Canada Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 251. Canada Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 252. Canada Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 253. Canada Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 254. Mexico Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 255. Mexico Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 256. Mexico Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 257. Mexico Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 258. Mexico Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 259. Mexico Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 260. Mexico Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. Mexico Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 262. Mexico Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 263. Mexico Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 264. Mexico Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 265. Brazil Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 266. Brazil Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. Brazil Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 268. Brazil Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 269. Brazil Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 270. Brazil Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 271. Brazil Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Brazil Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 273. Brazil Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 274. Brazil Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 275. Brazil Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 276. United Kingdom Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 277. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 278. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 279. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 280. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 281. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 282. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 284. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 285. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 286. United Kingdom Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 287. Germany Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 288. Germany Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 289. Germany Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 290. Germany Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 291. Germany Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 292. Germany Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 293. Germany Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 294. Germany Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 295. Germany Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 296. Germany Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 297. Germany Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 298. France Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 299. France Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 300. France Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 301. France Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 302. France Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 303. France Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 304. France Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 305. France Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 306. France Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 307. France Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 308. France Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 309. Russia Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 310. Russia Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 311. Russia Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 312. Russia Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 313. Russia Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 314. Russia Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 315. Russia Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 316. Russia Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 317. Russia Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 318. Russia Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 319. Russia Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 320. Italy Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 321. Italy Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 322. Italy Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 323. Italy Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 324. Italy Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 325. Italy Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 326. Italy Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. Italy Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 328. Italy Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 329. Italy Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 330. Italy Ophthalmic AAV Gene Therapy Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 331. Spain Ophthalmic AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 332. Spain Ophthalmic AAV Gene Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 333. Spain Ophthalmic AAV Gene Therapy Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 334. Spain Ophthalmic AAV Gene Therapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 335. Spain Ophthalmic AAV Gene Therapy Market Size, by Clinical Phase, 2017-2032 (USD Million)
TABLE 336. Spain Ophthalmic AAV Gene Therapy Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 337. Spain Ophthalmic AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 338. Spain Ophthalmic AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 339. Spain Ophthalmic AAV Gene Therapy Market Size, by Research Institutes, 2017-2032 (USD Million)
TABLE 340. Spain Ophthalmic AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 341. Spain Ophthalmic AAV Gene Therapy Market Size, by

Companies Mentioned

  • AbbVie Inc.
  • Adverum Biotechnologies, Inc.
  • Applied Genetic Technologies Corporation
  • Avista Therapeutics
  • Biogen Inc.
  • Cyagen Biomodels LLC
  • Editas Medicine, Inc.
  • Homology Medicines, Inc.
  • MeiraGTx Holdings plc
  • Neurophth Therapeutics, Inc.
  • Ocugen, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Regenxbio, Inc.
  • Spark Therapeutics, Inc.
  • ViGeneron GmbH

Related Topics

Related Reports

Gene Therapies in Ophthalmology - Competitive Landscape, 2026 - Product Image

Gene Therapies in Ophthalmology - Competitive Landscape, 2026

  • Report
  • 280 Pages
  • Global
From
Adeno-Associated Virus (AVV) Vectors in Gene Therapy Market Report 2026 - Product Image

Adeno-Associated Virus (AVV) Vectors in Gene Therapy Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Gene Therapy - Competitive Landscape, 2026 - Product Image

Gene Therapy - Competitive Landscape, 2026

  • Report
  • 550 Pages
  • Global
From
Gene Therapy Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Regions, Leading Players and Sales Forecast - Product Image

Gene Therapy Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Regions, Leading Players and Sales Forecast

  • Report
  • 972 Pages
  • Global
From
AAV Gene Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

AAV Gene Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.